Prizloncabtagene autoleucel

On the heels of last week’s teaming with Thermo Fisher Scientific, Cellular Origins has announced a collaboration with Johnson & Johnson to develop a scalable, end-to-end automated platform for autologous CAR-T cell manufacturing. “Cellular Origins has successfully shown that its platform is able to fully automate cell therapy manufacturing processes using validated, off-the-shelf third-party instruments in combination with mobile robots and Cellular Origins’ proprietary sterile fluid transfer technology,” according to the announcement. “As a next step, Cellular Origins is developing its first end-to-end, GMP-ready system for clinical manufacturing.” The partnership with J&J follows the biopharma company’s release earlier this month of promising data from a Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy. JNJ-4496 showed potential in treating patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who haven’t been previously treated with CAR T-cell therapy. In a separate announcement last week, Cellular Origins said it is collaborating with Thermo Fisher to deliver fully automated, robotic manufacture of cell and gene therapies (CGTs). The companies will combine Thermo Fisher’s cell culture and processing technology with Cellular Origins’ CGT robotic manufacturing platform, Constellation. Cellular Origins said the first customer installation of a robotically operated Constellation platform with the integration of Thermo Scientific Heracell VIOS AxD CO2 incubator technology has now been completed at the Digital and Automation Testbeds in the Cell and Gene Therapy Catapult’s Stevenage Manufacturing Innovation Centre, Stevenage, U.K., with extensive validation and testing to follow. “Both companies aim to achieve the largest production output of CGTs per square meter of manufacturing space, as well as the lowest labor requirements currently available within a digitally integrated framework,” according to the announcement.

MILAN, Italy I June 16, 2025 I AbelZeta Pharma, Inc. (“AbelZeta” or the “Company”), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, presented promising four-year clinical outcomes from 48 relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) patients treated with C-CAR039 (also known as Prizloncabtagene Autoleucel) in greater China, at the European Hematology Association (EHA) 2025 Congress. The study evaluated the safety and efficacy of C-CAR039, a novel anti-CD19/CD20 bi-specific CAR-T therapy. The dual-targeting approach to both CD20 and CD19 antigens aims to enhance therapeutic efficacy and reduce the likelihood of antigen escape, a common mechanism of resistance in B-cell malignancies. Key Findings: Safety Highlights: C-CAR039 has continued to show an excellent safety profile and deep and durable responses in R/R B-NHL patients, especially in those with R/R LBCL. These results continue to provide strong support for the curative potential of C-CAR039 as a next-generation therapy for R/R B-NHL. Late-stage clinical development is ongoing. “The long-term clinical outcomes data for C-CAR039 are highly encouraging, demonstrating sustained responses in patients with relapsed or refractory B-cell non-Hodgkin lymphoma,” said Tony (Bizuo) Liu, Chairman and Chief Executive Officer of AbelZeta. “These results underscore our commitment and corporate goal to develop transformative therapies that address significant unmet medical needs in cancer.” Dr. Yihong Yao, Chief Scientific Officer of AbelZeta, commented, “The strong clinical results of C-CAR039 demonstrate the added value of targeting CD20 in addition to CD19 in aggressive B-NHL. By addressing the limitations of single-antigen therapies – such as CD19 antigen escape – C-CAR039 enables deeper tissue penetration and more complete B-cell depletion. The durable responses observed support the continued advancement of C-CAR039 as a promising new treatment for patients with aggressive B-cell malignancies.” For more information on the study and access to the poster presentation, please visit the EHA Library poster here . AbelZeta previously presented 30-month Phase 1 clinical trial results at the 65th American Society of Hematology (ASH) Annual Meeting in December 2023, through oral presentation #1025 , as well as at EHA 2024, through poster presentation #P1475 . The data with 30 months follow up was published in Blood 2025 Apr 3;145(14):1526-1535 . AbelZeta Inc. (formerly known as Cellular Biomedicine Group, Inc.), entered into a worldwide collaboration and licensing agreement with Johnson & Johnson* in 2023 to develop and commercialize next-generation CAR-T cell therapies (excluding Greater China). The Phase 1 study for C-CAR039 was conducted by AbelZeta in China for the treatment of patients with B-cell non-Hodgkin lymphoma. Johnson & Johnson is evaluating the safety and efficacy of this asset (known as JNJ-90014496 outside of Greater China) through a separate study involving a global patient population. Phase 1b data for JNJ-90014496 were presented at EHA 2025 on Friday, June 13, informing the recommended Phase 2 dose and an initial assessment of safety, efficacy and pharmacokinetics in R/R LBCL patients. For more information, please visit Johnson and Johnson website: https://www.jnj.com/media-center/press-releases/johnson-johnsons-dual-targeting-car-t-cell-therapy-shows-encouraging-first-results-in-large-b-cell-lymphoma . *The legal entity to the worldwide collaboration and license agreement is Janssen Biotech, Inc., a Johnson & Johnson company. About AbelZeta Pharma, Inc. AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body’s own immune system to fight against hematological malignancies and solid tumors, as well as inflammatory and immunological diseases. AbelZeta advances research and development in its own GMP facilities at its centers of excellence for early-stage clinical studies, with a pipeline comprised of CAR-T therapies. SOURCE: AbelZeta Pharma